evidence: Weight gain was low (<1 kg) in both groups, with less gain with Gla-300 [LS mean difference −0.28 kg (95% CI −0.55 to −0.01); p = 0.039]
intervention: glargine 300 U/ml (Gla-300)
comparator: glargine 100 U/ml (Gla-100)
outcome: participants who reached target HbA1c after 6 months of treatment